dabrafenib mesylate
(duh-BRA-feh-nib MEH-zih-layt)
A drug used alone or with trametinib to treat low-grade glioma (a type of brain tumor) in children aged 1 year and older and certain types of anaplastic thyroid cancer, non-small cell lung cancer, melanoma, and other solid tumors that have a certain mutation (change) in the BRAF gene. It is also being studied in the treatment of other types of cancer. Dabrafenib mesylate blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Also called Tafinlar.